Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...

Structure Therapeutics Inc. (NASDAQ ... then the goal would be to combine them with GLP-1 agonist GSBR-1290 to treat patients with obesity. The third risk to consider would be in terms of ...

Demand for weight loss drugs targeting GLP-1 has exploded in recent years, leading to disruptions in supply chains. Here are ...

“We know that without a better cost management structure, most employers will be unable to cover GLP-1 benefits for weight loss, despite the extraordinary efficacy of the medications in reducing ...

Structure Therapeutics, Inc. Sponsored ADR ( (GPCR) ) has released its Q3 earnings. Here is a breakdown of the information Structure ...

SAN ANTONIO -- Patients with overweight or obesity lost an average one-fifth of their body weight with the highest dose of ...

Shares of Viking Therapeutics (NASDAQ: VKTX) fell on Monday, Nov. 4, despite some encouraging new data. Over the weekend, the ...

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Over the past three decades, there has been a startling increase in the prevalence of obesity across the U.S., at least ...

That's a better result than we've seen from oral anti-obesity candidates in development by Roche, Lilly, Novo Nordisk, and Structure Therapeutics. Sales of GLP-1 drugs are expected to soar from ...

We actually call these GLP-1 patients GLP-1 orphans ... we really evaluated the entire structure across all departments and we looked at ways to gain efficiency and work towards profitability at the ...